In a case-control study aimed at localizing disease variants, association between a marker and the disease status is often tested by comparing the marker allele frequencies among cases and controls. These marker allele frequencies are expected to be different if the marker is associated with the disease. The power of the commonly used allele based test is based on the marker allele frequency; markers with a low minor allele frequency have less power to be detected (if they are associated with the disease), than markers with high minor allele frequency. Therefore the strategy of selecting markers for follow-up study based on their p-values, favors markers with a high minor allele frequency.
Introduction
To locate disease variants and dichotomous trait loci, association studies of genetic markers are often conducted with a case-control design. Several genetic association tests have been proposed (see e.g. [2, 15] ). One simple and perhaps one of the most natural test, is the singular marker allele based test that is based on the difference of the sample marker allele frequencies in cases and controls.
A marker is associated with the disease or trait if it is in linkage disequilibrium (LD) with one of the causal variants (see e.g. [15] ). On average, the larger the degree of LD, the smaller the p-value of the association test. However, the p-value obtained with the (commonly used) singular marker allele based test is also a function of the marker allele frequency; markers with high minor allele frequencies (MAFs) have more power to be detected than markers with low MAFs. The strategy of selecting interesting markers for follow-up study based on their p-values only, is therefore biased towards markers with high MAFs.
Several other strategies for prioritizing the markers for follow-up studies have been proposed and compared, like ranking markers based on the Bayes Factor signal ( [12, 13] ), the likelihood ratio signal ( [9] ), frequentist factor signal ( [11] ), and PrPES signals ( [8] ). [9] compared these strategies, including ranking markers based on the p-values of the allele based test and CochranArmitage-trend test, by applying them to two data-sets. The markers with the smallest p-values obtained from the allele based test are also top-ranked by the other methods. Some strategies down-weight markers with small MAF even more than the allele based test does.
In this paper we propose an allele based test for testing association in case-control studies that does not favor markers with high minor allele frequencies. It is shown that the test has more power than the commonly used allele based test if the minor allele frequency of the marker is quite low. The proposed test-statistic is found by standardizing the difference of sample allele frequencies in a different way than the commonly allele based test does. An explicit asymptotic power function is derived and finite sample properties are obtained by simulation studies. The test will be applied to data.
"Missing" heritability refers to the fact that for many traits, only a small proportion of the variability in the population can be explained by causal variants that have been identified up to now (see e.g. [5] ). One possible explanation for this "missing" heritability is the presence of low-frequency variants of relatively strong effect on disease risk. Indeed, rare variants found by resequencing have already been described to affect complex diseases ( [7] ). In the light of the current interest in detecting association between complex phenotypes and low-frequency variants and localizing causal variants with small minor allele frequencies, the implications of the present paper are expected to be of relevance.
Methods

Setting
The case-control status for a random individual in the general population is denoted by X, X = 1 for a case and X = 0 for a control. The fractions of cases and controls in the total population are denoted by π = P(X = 1) and 1 − π = P(X = 0). There may be multiple causal variants; the aim in association studies is to locate these variants. We initially assume that any given marker is in linkage disequilibrium with at most one causal variant. Therefore, it is sufficient to consider the situation where there is only one causal variant. Suppose the causal variant is biallelic with alleles A 1 and A 2 and with corresponding allele frequencies p 1 and p 2 = 1 − p 1 in the total population. In case the causal variant is not biallelic, the second allele, A 2 , could be regarded as all alleles which are not the A 1 -allele. We denote the fraction of individuals with the disease (X = 1) among those individuals with genotype (A i , A j ) at the causal variant by π ij = P(X = 1|A i A j ) for i, j = 1, 2 and we assume that π 12 = π 21 .
We consider a biallelic marker which may or may not be in proximity with the causal variant. One of the marker alleles is denoted as M 1 and the other allele as M 2 . The allele frequencies for M 1 and M 2 in the general population are denoted as q 1 and q 2 = 1 − q 1 and the M i allele frequencies among the controls and cases are denoted as q i|0 = q i|X=0 and q i|1 = q i|X=1 for i = 1, 2.
A common measure for the degree of LD between a marker and a causal variant is given by the quantity
haplotype-frequency in the total population (see for instance [3] ). By definition ∆ ij = cor(1 A i , 1 M j ) with, for a randomly chosen haplotype, 1 A i and 1 M j the indicator functions which equal 1 if the causal variant is A i and 0 otherwise, and similar for the marker allele M j . In the Appendix A in the Supplementary Material it is derived that
with ∆ = ∆ 11 . So, the relative difference between the allele frequencies among the controls and cases at the causal variant (the quotient on the right hand side of the expression) is passed on to the neighboring markers by multiplying this relative difference by ∆, the degree of linkage disequilibrium between the alleles at the marker and the causal variant. From this formula it can be directly seen that the M 1 allele frequencies among the controls and cases equal if the marker is in linkage equilibrium with the causal variant, i.e. ∆ = 0. In order to find markers that are associated with the disease or, actually, are in linkage disequilibrium with the causal variant, case-control data is collected. Suppose we have a sample of R individuals from the cases and S individuals from the controls; R and S are fixed and non-random. Their sum is denoted as N = S + R. Since every genotype consists of two alleles, there are actually 2R and 2S alleles from the cases and controls, respectively. The number of M 1 alleles among the cases and controls are denoted as R 1 and S 1 , respectively. For the number of M 2 alleles, the notation is analogues: R 2 and S 2 for the cases and controls. Note that R 1 + R 2 = 2R and S 1 + S 2 = 2S. Based on these data the fraction of M 1 alleles among the controls and the cases can be estimated asq 1|0 = S 1 /(2S) andq 1|1 = R 1 /(2R).
In the following two allele based association tests are described for testing the null hypothesis H 0 : q 1|0 = q 1|1 against the alternative H 1 : q 1|0 = q 1|1 . The first test we describe, is the commonly used test. This test is based on the differenceq 1|0 −q 1|1 , standardized so that the test-statistic is asymptotically standard normal distributed under the null hypothesis of no association. Calculations will show that by the way of standardizing, markers with a low minor allele frequency have less power to be detected under the alternative hypothesis, than markers with a high minor allele frequency. The test we propose is also based on the differenceq 1|0 −q 1|1 , but standardized in a different way. In Section 3 the power of the two tests are compared.
Commonly used allele based association test
The commonly used allele based test-statistic for testing the null hypothesis H 0 : q 1|0 = q 1|1 against H 1 : q 1|0 = q 1|1 is given by
The unknown frequencies q 1|0 and q 1|1 in V 0 and V 1 are, usually, estimated byq 1|0 andq 1|1 , so that V is asymptotically unbiased under the null and alternative hypothesis. For λ = R/N the fraction of sampled cases, the variance V equals
. For large sample sizes, the test-statistic T has, approximately, a normal distribution with mean
and variance 1, where
The equality in (3) follows from (1) . Under the null hypothesis that q 1|0 = q 1|1 (i.e. ∆ = 0), T has, asymptotically, a standard normal distribution, whence H 0 is rejected for |T | ≥ z α/2 , with z α/2 the upper-α/2-quantile of the standard normal distribution. The two-sided power-function of the test (approximately) equals, for large sample sizes,
The power of the test is controlled by the product √ mB∆Q. The first term, √ m, is specific for the way of sampling and is, therefore, equal for every marker. The second term, B, is specific for the causal variant and is equal for all markers that are in linkage disequilibrium with the same causal variant. The third term, ∆, measures the degree of LD between the marker and the causal variant and its value varies over the markers. The last term, Q, depends on the marker. Under the null hypothesis that a marker is not associated with the disease Q = 1, but under the alternative Q is either smaller or larger than 1, depending on the (conditional) marker allele frequencies. That means that the markers in the association study are weighted; markers with Q > 1 do get more power to be detected than markers with Q < 1.
Allele based test for markers with low MAF
Define the test-statistic
, wherê π is an estimate of the disease prevalence P(X = 1). This estimate cannot be obtained from the samples of cases and controls, but should be estimated based on external data. For many diseases, an estimate of the population prevalence π is available, for instance in the literature or in national registries. The test-statistics W and T are related via the relationship W = TQ −1 , withQ an estimate of Q in (4); it is found by inserting the estimatesq 1 andq 2 (as just defined) and the marker sample frequencies among cases and controls. By the law of large numbers,Q approximately equals Q for large samples and from Slutsky's lemma and the continuous mapping theorem (see e.g. [10] ) it follows that W has, approximately, a normal distribution with mean
and variance Q −2 . Under the null hypothesis, q 1|0 = q 1|1 , ∆ = 0 and Q = 1 and W has, asymptotically, a standard normal distribution, whence H 0 is rejected for |W | ≥ z α/2 for z α/2 the upper α quantile of the standard normal distribution. Under the null
, no matter the value ofπ. That means that, even if the estimate of π is far away from the true value, the type I error of the test will still be approximately correct if the sample sizes are large enough. The two-sided power function for W is given by
The power functions for W and T are very similar, but differ in the way Q is the expression. In the power function for W , also the quantile z α/2 is multiplied with Q. If Q = 1 (i.e. under H 0 ) the power functions equal (to α). Under the alternative hypothesis either Q > 1 or Q < 1.
If the sample size is large, this will probably also hold forQ (sinceQ converges in probability to Q if alsoπ converges in probability to π). From the definitions of T and W , it follows that |W | > |T | ifQ < 1 and |W | < |T | ifQ > 1; ifQ < 1 the test based on W is more powerful, whereas the test based on T is more powerful ifQ > 1. In Appendix B in the Supplementary Materials it is shown that, if M 1 is positively correlated with the risk allele (A 1 or A 2 ) and q 1 is sufficiently small, Q will be smaller than 1. However, if M 1 is negatively correlated with the risk allele, Q > 1. If the risk allele is the minor allele and q 1 is small, strong negative correlation with the risk allele are not possible within the parameter space of the genetic model. The latter can be easily seen from the following. Remind that 
Generalization of the test-statistic: W δ
The test-statistic W can be generalized by allowing other values in stead of π. Define the test-statistic
For δ =π, this statistic Wπ equals W and, furthermore, W δ = TQ −1 δ withQ δ an estimate for Q δ with Q 2 δ = q 1 q 2 /(δq 1|0 q 2|0 + (1 − δ)q 1|1 q 2|1 ) (similar to Q 2 as defined before). The estimate of Q δ is found by inserting estimates of the allele frequencies, like is done for Q.
Under the null hypothesis that q 1|0 = q 1|1 and the denominator of W δ converges in probability to √ q 1 q 2 , notwithstanding the value of δ. That means that under the null hypothesis, the teststatistic W δ has, approximately, a standard normal distribution, for large sample sizes. So, the null hypothesis of no association is rejected if |W δ | > z α/2 . If δ = π, the denominator converges to √ q 1 q 2 under the alternative hypothesis. So, only in that case the mean of the test-statistic approximates √ mB∆ for large sample sizes. The test is most powerful if, under the alternative hypothesis, the denominator is minimized. If M 1 is the minor allele and positively correlated with the disease and, thus q 1|0 < q 1|1 < 0.5, the test is optimal for δ = 0 and least optimal for δ = 1. If 0.5 > q 1|0 > q 1|1 (the minor allele M 1 is negatively correlated with the disease), it is the other way around. For 0 < δ < 1, the power is in between the minimum and maximum. In practice it is unknown whether the minor allele M 1 is positively or negatively correlated with the disease.
Combined test of W and T
The two test-statistics W and T are linked via T = WQ. IfQ > 1, the test with test-statistic T is more powerful, whereas the opposite holds ifQ < 1. IfQ = 1 then T = W and the two tests are equivalent. To have best of both of tests, the two tests could be combined. Define
as the combined test-statistic. By combining the law of large numbers, Slutsky's lemma and the continuous mapping theorem (see e.g. [10] ), U has asymptotically a standard normal distribution under the null hypothesis of no association; the null hypothesis is rejected for |U | ≥ z α/2 . The asymptotic power function for U equals the one of W if Q < 1 and of T if Q > 1. In a similar way the test-statistics W δ and T could be combined.
Multiple causal variants
Suppose there are multiple causal variants, but every marker is in linkage disequilibrium with at most one causal variant. The value of B is specific for the causal variant and will, therefore, be the same for all markers which are in linkage disequilibrium with this causal variant. Since the power function (and the p-value) depends on the value of B, markers can only be ranked on their p-values locally; for all markers which are in linkage disequilibrium with the same causal variant. In practice it is unknown whether there is only one or multiple causal variants. One should be careful when comparing p-values for markers at different chromosomes or located far apart.
Measuring the effect size
For the markers that show significant association with the disease status, the effect size is of interest. When testing based on the test-statistics T or W , the difference between the allele frequencies among cases and controls, q 1|0 − q 1|1 , could be used as a measure of effect, but this difference is difficult to interpret. In practice the Cochran-Armitage test or the test-statistic T , is often used for testing association, whereas an effect size in terms of odds ratios is estimated by fitting a logistic regression model ( [14] ). It would be more natural to use the same statistic for testing association and estimating an effect size. This can be done within a logistic regression model, but also based on the test-statistics W or T . The effect size defined as
can be estimated and a corresponding confidence interval can be constructed. This can be seen by writing this fraction as (using Bayes theorem) q 1|0 /q 1|1 = 1 + (q 1|0 − q 1|1 )/q 1|1 and noting thatq 1|1 is consistent by the law of large numbers. This quantity is not based on any model assumptions, like in a logistic regression model, and is therefore very appropriate for quantifying the marker effect size. When determining a quantity for measuring an effect size, it is important to keep in mind what the aim of the study is. In case one aims to estimate the disease risk based on the observed genotypes at markers which are possibly not the causal variant, odds ratios for different markers would be appropriate. However, in case one aims to find the causal variant, one may prefer to use a measure that tries to quantify the distance between markers and a causal variant, or at least orders the markers with respect to their distance to the causal variant. Of course, it is not possible to measure the physical distance between markers and a causal variant, but, locally, the markers can be ordered with respect to the degree of linkage disequilibrium with a causal variant. In the previous subsection we have seen that W/ √ m ≈ B∆, where B is equal for all markers that are in LD with the same causal variant. That means that ranking the markers (in a small region of the chromosome) based on the test-statistic |W |, is equivalent to ranking them based on (an estimate of) the degree the marker is in LD with the causal variant (∆). Although, it is known that ∆ between markers and a causal variant is not necessarily a monotone function with the physical distance between the two, it is expected that there is a positive relationship and the causal variant will be located nearby the markers which are strongest in LD with the causal variant.
Results
This section is divided into two subsections. In the first subsection the asymptotic power functions of the two tests are compared. In practice, the sample sizes are finite. In the second subsection we perform simulation to study the type I error for finite samples, and the effect of the extra variability due to the fact that π is estimated.
Comparison of the asymptotic power functions
We define the A 1 -allele at the causal variant as the high risk allele and the disease probabilities are taken equal to π 11 = 0.60, π 22 = 0.10 and for the additive model π 12 = (π 11 + π 22 )/2 = 0.35.
In Figure 1 the asymptotic power function is given as a function of q 1 (first and second plot) and of ∆ (third plot). In all cases R = S = 1000 and α = 1.0e −8 . In the first plot p 1 = 0.05 and p 1 = 0.15 in the second plot. In both cases ∆ = 0.3. The power function for the test-statistic W is plotted as a continuous line and for T as a dashed line. In the most right plot in Figure 1 , the power function as a function of ∆ is given. Now, p 1 = 0.05 and q 1 equals either p 1 or 3p 1 . Again, the dashed lines represent the power for the test with test-statistic T (q 1 = p 1 lower line, q 1 = 3p 1 upper line) and the continuous lines for the test with test-statistic W (the two lines overlap). For all plots we inserted the true value of π in the power function, because it will be shown below that the power function is robust against misspecification of the parameter π.
From the plots it can be concluded that the test based on test-statistic W is more powerful than the one based on T for the genetic models described above. The power based on W is approximately constant as a function of q 1 , whereas the power based on T increases with q 1 . So, W does not, a-priori, favors markers with a large minor allele frequency. This makes the p-values comparable across markers. This does not hold for T . The power functions were plotted for more genetic models, including the dominant and the recessive model. As long as the correlation between A 1 and M 1 is positive, the conclusions remain the same.
If the minor allele M 1 is negatively correlated with the causal allele A 1 , the theory tells us that the test based on T is more powerful. We consider the same setting as before. In the left plot of Figure 2 the power functions for the two tests are given as a function of q 1 for ∆ = −0.40 and p 1 = 0.60. The power of the test based on T is indeed higher. However, note the low power of both tests. In the right plot of Figure 2 the power is plotted as a function of ∆. Again, the test T is more powerful if ∆ < 0.
Misclassification of π
The denominator of the test-statistic W contains the parameter π, the prevalence of the disease, which cannot be estimated from the case-control data itself, but has to be estimated based on data from a different source. Misspecification of this parameter affects the power of the test. Therefore, the power function is considered for different values of the estimateπ. So, actually the power of the test based on W δ is considered for different values for δ near π. That means that misclassification of π will never lead to a test with inflated type I error (if the sample size is big enough), but to a different test which has a priori a slight preference for markers with either small (ifπ < π) or large (ifπ > π) minor allele frequencies.
The power function was computed for exactly the same models as was done before. The results are given in Figure 3 . The power was computed forπ = 0.2 (lowest continuous lines) π = π = 0.125 (continuous line in the middle),π = 0.075 (upper line). Since the power function for T does not contain π, only one curve is found; the dashed line. More models were considered. In all cases similar results were obtained. We conclude that allele based test for testing with the test-statistic W is robust against small misspecification of π. It can be seen that only for δ ≈ π the lines are more or less constant; the power is not affected by the marker allele frequency. Above the fat line, the power functions are slightly decreasing as a function of q 1 , and below the fat line, the power is increasing.
Finite samples
The power function and the computation of p-values are based on asymptotic normality of the test-statistic W . In practice the sample sizes are finite and not infinite. Therefore the normality approximation may not be exact and a continuity correction may improve this approximation. A correction can be done in multiple ways. We used the following:
where the "maximum" could be replaced by the "minimum" if one prefers to correct less. The null distribution of the test-statistic is asymptotically standard normal. In practice the number of observations is not infinite and the finite sample distribution may be different from the asymptotic distribution. We performed a simulation study to check the type I error for the three tests. Like before we take p 1 = 0.10, π 11 = 0.60 and π 22 = 0.10 in the additive model. Since we do the simulation under the null hypothesis ∆ = 0. We simulate 100,000,000 times R cases and S controls from the model given in Table 1 , compute the test-statistic T, W and W cor , the corresponding p-values, and compute an estimate of the type I error as the fraction of p-values smaller than α. The results are given in Table 1 . From the table it can be seen that the type I error for the test based on W is slightly inflated especially if the sample sizes are small and the maf of the marker is low. This inflation disappears if the sample size or the maf grows. After continuity correction as described in (10) there seems to be still an inflation, but this is smaller already.
In the previous example the value of π is 0.15. If the prevalence of the disease in the population is lower, the sample size is small (around 500 cases and 500 controls) and the MAF of the marker is also quite low (0.10 or lower), the type I error inflation may become unacceptable. In that case one could decide to insert a higher value of δ, what diminish the type I error, but decreases the power of test under the alternative hypothesis.
We also performed several simulation studies under the alternative hypothesis. In all cases the power functions based on finite samples were very similar to the asymptotic power function (results not shown).
Combined Test
We perform several simulation studies to study the performance of the combined test with teststatistic U . The results are as expected. For large sample sizes the null distribution is close to a standard normal distribution (concluded from QQ-plots and histograms of the p-values) and the power-function equals the maximum of the power-functions for T and W . For low sample sizes and/or low minor allele frequencies at the marker, the null distribution deviates from the standard normal distribution in just one tail. For all observations in that tailQ < 1 (the test-statistic U equals W ). This was also seen for the test-statistic W and is therefore as expected. This problem can be easily solved by recalculating the small p-values in the tail by permutations.
The observations in the opposite tail all hadQ > 1 (U equals T ) and the fit with the standard normal distribution is good (as expected, since the null distribution for T is standard normal also if the sample size is low). The results of these simulation studies are not shown in this paper, because, to our opinion, the results are as expected and do not add much to the paper.
Discussion
Several methods have been proposed for selecting markers for follow-up in a case-control association study. One of the most popular test is the allele based test that considers the difference of marker allele frequency among cases and controls. A disadvantage of this test is its preference for markers with high minor allele frequencies; markers with low minor allele frequency have less power to be detected than markers with a high minor allele frequency.
In this paper a new allele based association test for finding markers that are associated with a disease is proposed. The test is model-free and the test-statistic can be computed easily and fast. Moreover, the asymptotic null distribution of the test-statistic is known what makes the computations of p-values fast; permutations are not necessary. The power of the test is higher than for the commonly used test for many genetic models that are of practical interest. For those models, the lower the minor allele frequency is, the more power is gained by using the new test. This is mainly caused by the fact that the power of the proposed test is approximately constant as a function of the marker allele frequency; the proposed test does not favor markers with a high minor allele frequencies. So, ranking the markers based on their p-values becomes a more objective way of selecting interesting markers for follow-up studies and, because of its high power for markers with a low minor allele frequency (compared to the existing test), the proposed test may reveal interesting regions for follow-up study.
The proposed test-statistic depends on the parameter π, the prevalence of the disease. This parameter cannot be estimated based on the data itself, but should be estimated from external data. For most diseases, population risks are available, for instance from national registries. In the paper it is shown that the type I error is hardly affected by misspecification of π, because under the null hypothesis the parameter (almost) drops out from the test-statistic if the number of observations is large. In practice, it is quite common to estimate nuisance parameters in the model based on external data and to assume that these estimated nuisance parameters are known when performing statistical tests or constructing confidence intervals for the parameter of interest. The extra uncertainty due to the estimation of these nuisance parameter are often not taken into account what may lead to wrong type I errors, in general . In [4] the effect on the type I error for the likelihood ratio test-statistic is studied. We generalized the model by allowing other values for π between zero and one. This may yield higher power for some markers, but the a priori preference for markers with high or low MAFs is back again. Moreover, by taking values near the boundary (zero or one), the type I error may increase above acceptable levels. We therefore advice to use π as first choice. However, if π itself is low (near zero) and the sample size is not huge, the type I error may be inflated if the marker MAF is low. In that case one could decide to impute a higher value for δ in the denominator of the test-statistic, so δ > π, to give up some power and lower the number of false discoveries. This was seen in the simulation study in this manuscript.
In the derivation of the test-statistic W as well as in the simulation studies we assume that the alleles at a marker and causal variant are in Hardy-Weinberg equilibrium. However, deviations from Hardy-Weinberg equilibrium can inflate the chance of a false-positive association ( [6] ). In [6] an test-statistic that accounts for deviation from HWE is introduced; an extra term is added to the variance in the denominator of the test-statistic. Our test-statistic can be adjusted in a similar way, what makes the type I error of the test robust against deviation from Hardy Weinberg.
When the Hardy-Weinberg proportions hold in the total population, the allele-based test T and the Cochran-Armitage Trend test for the additive model are asymptotically equivalent under the null hypothesis ( [1, 15] ). Since T and W are also asymptotically equivalent under the null hypothesis, this also holds for W and the Cochran-Armitage Trend test (CATT). Under the alternative hypothesis, the power functions differ. Based on a simulation study, [15] show that the power of the allele-based test T and the CATT for additive models are, nevertheless, very similar, with a slightly higher power for the allele-based test T under the recessive model and for the CATT under the dominant model (for genetic models they consider). For the genetic models for which the test based on W is more powerful than the test based on T , the test based on W is also more powerful than the CATT.
Another association test is a score test based on a logistic regression model. The score test statistic equals the CATT ( [15] ), from which it directly follows from the previous paragraph that in many interesting settings, the allele-based test W is also more powerful than the score-test for a logistic regression model.
For some genetic settings the test based on T is more powerful than the test based on W . We therefore combined the two test-statistics to a test-statistic U that always has an (asymptotic) power of at least the tests T or U . Although the test-statistic is more complicated now, it still has asymptotically a standard normal distribution under the null hypothesis and p-values can be easily obtained.
A part of the missing heritability might be explained by causal variants with a low minor allele frequency. The test proposed in this paper, may help detecting a part of the undiscovered causal variants.
